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The bone marrow (BM) niche comprises multiple cell types which regulate 2 
hematopoietic stem/progenitor cell (HSPC) migration out of the niche and into the 3 
circulation. Here, we demonstrate that osteocytes, the major cellular component of 4 
mature bone, are regulators of HSPC egress. Granulocyte colony-stimulating factor 5 
(G-CSF), used clinically to mobilize HSPCs, induces changes in the morphology and 6 
gene expression of the osteocytic network that precedes changes in osteoblasts. 7 
This rapid response is likely under control by the sympathetic nervous system, since 8 
osteocytes express the β2-adrenergic receptor and surgical sympathectomy prevents 9 
it. Mice with targeted ablation of osteocytes or a disrupted osteocyte network have 10 
comparable numbers of HSPCs in the BM, but fail to mobilize HSPCs in response to 11 
G-CSF. Taken together, these results indicate that the BM/bone niche interface is 12 
critically controlled from inside of the bone matrix, and establish an important 13 






Hematopoietic stem/progenitor cells (HSPCs) reside in specific niches that 2 
control their fate in the bone marrow (BM). Among many candidates for the niche 3 
(Wang and Wagers, 2011), osteoblasts at the endosteal surface are well investigated 4 
(Arai et al., 2004; Calvi et al., 2003; Visnjic et al., 2004; Zhang et al., 2003) and are 5 
associated with granulocyte colony-stimulating factor (G-CSF)-induced HSPC 6 
mobilization (Christopher and Link, 2008; Katayama et al., 2006; Kawamori et al., 7 
2010). Niche function is maintained through a balance between a suppressive signal 8 
from the sympathetic nervous system (SNS) (Katayama et al., 2006; Mendez-Ferrer 9 
et al., 2008) and a supporting signal from the macrophages (Chow et al., 2011; 10 
Christopher et al., 2011; Winkler et al., 2010). G-CSF increases sympathetic tone 11 
and eliminates endosteal macrophages, which leads to suppression of the 12 
osteoblastic niche through the dual negative regulations in the BM. However, the 13 
osteoblastic niche is located at the interface between the BM and bone, and 14 
regulatory signals from inside the bone are unknown. 15 
Embedded in bone matrix are osteocytes, which are the most abundant 16 
cells and constitute more than 90% of all bone cells (Bonewald, 2011). Osteocytes 17 
differentiate from osteoblasts, and they extend long cell processes that connect with 18 
 4 
neighboring osteocytes, as well as osteoblasts or cells lining the bone endosteal 1 
surface. Osteocytes have been shown to control the functions of osteoblasts and 2 
osteoclasts by integrating mechanical signals (Tatsumi et al., 2007).  3 
 In this study, the role of bone-embedded osteocytes in the regulation of the 4 
endosteal niche was investigated. We found that osteocytes were essential for the 5 




Early Response of Osteocytes to G-CSF 2 
In order to assess the influence of G-CSF on osteoblastic versus osteocytic 3 
functions, we analyzed the kinetics of gene expression during treatment with G-CSF. 4 
Subcutaneous (s.c.) injection of G-CSF into wild type (WT) mice was performed 5 
every 12 hours (Figure 1A). According to this schedule, the mobilization of HSPC 6 
occurred from the 4th dose, was markedly increased at the 6th dose, and the 8th 7 
dose indicated the point of robust mobilization (Figure 1B). We analyzed the gene 8 
expression level of bone samples at the indicated doses of G-CSF. After the BM was 9 
flushed out, RNA was extracted from the femur and then analyzed. While the 10 
markers of osteoblasts, osteocalcin, type 1 collagen (Col1a1), and osteopontin, 11 
started to decrease at the 6th dose during modest mobilization, the expression of 12 
osteocyte-specific genes, such as E11/gp38, phosphate regulating endopeptidase 13 
homolog X-linked (Phex), neuropeptide y (NPY), matrix extracellular 14 
phosphoglycoprotein (MEPE), and sclerostin (SOST), exhibited rapid suppression at 15 
the 1st or 2nd dose when no mobilization was observed yet (Figure 1C). Furthermore, 16 
in order to assess the effect of G-CSF in osteoblasts and osteocytes separately, we 17 
digested long bones enzymatically according to the recent work by Stern et al. (Stern 18 
 6 
et al., 2012). Bone cells were isolated as osteoblast- or osteocyte-enriched fractions 1 
after one dose of G-CSF treatment. Early fractions (Fr1+2) expressed osteoblast 2 
markers, such as osteocalcin and Col1a1, and osteocyte gene expression increased 3 
as the digestion progressed. These results suggested that early fractions (Fr1+2) 4 
contained osteoblasts from the endosteal surface, and late fractions (Fr7+8, Fr9+10) 5 
contained osteocytes embedded in mineralized bone (Figure 1D). 6 
Osteocyte-enriched fractions also expressed osteoblast markers, such as 7 
osteocalcin, Col1a1, and osteopontin, as much as the osteoblast-enriched fraction. 8 
Interestingly, one dose of G-CSF treatment down-regulated the osteocyte markers 9 
as well as the osteoblast markers, but only in the osteocyte-enriched fractions 10 
(Figure 1D). These data suggested that osteocytes responded earlier than 11 
osteoblasts to G-CSF with altered gene expression and raised the possible role of 12 
osteocytes as initiators of G-CSF-induced mobilization.  13 
A marked change in the appearance of the osteocyte network was noted 14 
after 8 doses of G-CSF (Figure 2A). We observed the osteocytes in three different 15 
regions of the femur; cortical bone in the metaphysis, cortical bone in the diaphysis, 16 
and trabecular bone in the metaphysis (Figure 2B). The number and thickness of 17 
cellular processes that connect the osteocytes with endosteal osteoblasts were 18 
 7 
reduced (Figure 2C). These morphological changes were more prominent in the 1 
osteocytes near the endosteal surface, while the deeply embedded osteocytes were 2 
less affected (Figures 2C and 2D). Taken together with the results of gene 3 
expression, these data suggested that G-CSF administration induced functional and 4 
morphological changes in the osteocytes.  5 
 6 
Regulation of Osteocytes by Sympathetic Nervous System 7 
We have previously proposed the concepts that 1) G-CSF may activate the 8 
outflow of the SNS, 2) released catecholamine stimulates β2-adrenergic receptor 9 
(β2-AR) on osteoblasts, 3) β2-AR signal strongly suppresses osteoblast activity, and 10 
4) HSPCs are released from suppressed osteoblasts (Katayama et al., 2006). To 11 
explore whether adrenergic signal is involved in the changes in the osteocyte 12 
network triggered by G-CSF, we visualized sympathetic nerve endings in the 13 
endosteum. Tyrosine hydroxylase (TH) is a key enzyme that converts tyrosine to 14 
dopamine and norepinephrine in adrenergic neurons, which can be a useful marker 15 
to determine the distribution of adrenergic neurons in the BM and bone. We 16 
confirmed that TH-positive nerve fibers reached the endosteal bone surface (Figure 17 
3A), and 8 doses of G-CSF did not change their appearance (data not shown). 18 
 8 
Interestingly, osteocytes near the endosteum expressed β2-AR (Figures 3B and 3C). 1 
Of note, osteocyte processes that extended to the endosteal surface were positive 2 
for β2-AR (Figures 3D and S1A), which suggested that osteocytes could sense 3 
adrenergic signals through their processes.  4 
      To further explore whether the alteration in osteocyte gene expression caused 5 
by G-CSF is mediated by SNS, the gene expression in the bone of surgically 6 
sympathectomized mice was analyzed. We expected that gene alteration in 7 
osteocytes induced by G-CSF would be abolished in the denervated bone if 8 
osteocytes were affected by SNS signal during mobilization process. Sectioning of 9 
both femoral and sciatic nerves led to complete disruption of SNS in the tibia, and 10 
this procedure abolished the circadian rhythm regulated by SNS (Mendez-Ferrer et 11 
al., 2008). We confirmed that TH-positive neurons in the BM were diminished after 12 
surgical denervation, which indicated a successful sympathetic nerve lesion (Figure 13 
S1B). The gene expression profile of osteocytes between the denervated tibiae after 14 
the BM was flushed out and the contralateral sham-operated control side was then 15 
compared. As expected, two doses of G-CSF administration decreased gene 16 
expression of E11/gp38 and Phex significantly in the sham-operated bone (Figure 17 
3E). Intriguingly, there was decreased expression of E11/gp38, Phex, and NPY after 18 
 9 
denervation, but G-CSF administration failed to further decrease the expression of 1 
these genes (Figure 3E). Although the denervation could cause the decrease in 2 
mechanical load due to ambulatory disturbance to some extent, these results 3 
suggested that osteocytic function could be regulated by SNS. Similar results were 4 
observed in the osteoblast markers, namely osteocalcin and Col1a1 (Figure S1C); 5 
however, it could be due to the alteration in osteocytes because these osteoblastic 6 
genes were also expressed in osteocytes (Figure 1D). These data suggested that 7 
osteocytic function was regulated through SNS, and together with the increased 8 
sympathetic tone following G-CSF treatment, the results raised the possibility that 9 
osteocytes could mediate the HSPC mobilization by G-CSF through a sympathetic 10 
tone. 11 
 12 
Failure of G-CSF to Mobilize HSPCs in the Absence of Osteocytes 13 
To directly address osteocytic involvement in G-CSF-induced HSPC 14 
mobilization, we utilized transgenic (Tg) mice; in which inducible and specific ablation 15 
of osteocytes could be achieved through targeted expression of diphtheria toxin (DT) 16 
receptor under dentin matrix protein-1 (DMP-1) promoter. In this model, a single 17 
dose of DT injection caused ablation of osteocytes and disrupted their network 18 
 10 
(Figure 4A), which resulted in the generation of “osteocyte-less (OL) mice” (Tatsumi 1 
et al., 2007). Strikingly, G-CSF-induced mobilization was severely impaired in OL 2 
mice (Figures 4B-4D), including stem cells, as assessed by long-term competitive 3 
repopulation assay (Figures 4E and 4F). On the other hand, the number of HSPCs in 4 
the BM was normal in OL mice (Figures 4G-4I). These data indicated that HSPCs 5 
could not be mobilized from the BM into the circulation by G-CSF in OL mice. In 6 
addition, the number of progenitors in the spleen in steady state was drastically 7 
decreased after osteocyte depletion (Figure 4J), which suggested that the 8 
physiological mobilization was also suppressed.  9 
To assess the role of osteocytes for HSPC engraftment process, we tried 10 
to use OL mice as the recipient of BM transplantation. However, OL mice were so 11 
fragile that they died within a few days after irradiation. Instead, homing ability of WT 12 
colony forming progenitors into OL mice BM at three hours after intravenous 13 
transplantation was analyzed. The results revealed that the homing of HSPC in OL 14 
mice was not impaired (Figure 4K) despite its mobilization defect. These results 15 
suggested that osteocytes could specifically participate in the mechanism of HSPC 16 
egress from the BM.  17 
 18 
 11 
Alteration of Osteoblast Morphology and Function by Osteocyte Ablation 1 
We hypothesized that the mobilization defect in OL mice was due to an 2 
impairment of osteoblastic niche function, in light of the emerging concept that 3 
osteocytes communicated with endosteal osteoblasts through dendritic processes 4 
and regulated the function of osteoblasts (Taylor et al., 2007). Histological 5 
examination of femoral bone at 11 days after DT administration revealed that 6 
endosteal osteoblasts became flat in shape in OL mice (Figures 4L and 4M). The 7 
levels of osteocalcin mRNA in bone tissue and osteocalcin protein in plasma were 8 
dramatically decreased in OL mice (Figures 4N and 4O). In addition, 9 
immunofluorescence staining revealed that osteocalcin-positive osteoblasts were 10 
reduced in OL mice (Figures 4P–4R). In the DMP-1 DTR Tg mice, specific 11 
expression of DTR in osteocytes had been proven previously (Tatsumi et al., 2007). 12 
It was also confirmed that osteoblasts were not ablated or subjected to any 13 
morphological changes at 2-3 days following DT administration when empty lacunae 14 
had already appeared (Figures S2A and S2B). The number of osteocalcin-positive 15 
osteoblasts in OL mice at 2-3 days after DT administration was comparable to that of 16 
WT control (Figures S2C and S2D). These data suggested that the changes in 17 
osteoblasts were secondary effects of osteocyte depletion rather than a direct effect 18 
 12 
of DT on osteoblasts.   1 
 2 
Alteration of Microenvironment in Bone Marrow by Osteocyte Ablation 3 
It is well known that the expression of the chemokine, CXCL12, in the BM 4 
is reduced at both protein and mRNA levels during G-CSF-induced mobilization. 5 
Thus, it is widely thought that its reduction is a key event for HSPC release from the 6 
BM to the circulation as a consequence of diminished chemoattraction (Levesque et 7 
al., 2003; Petit et al., 2002). Despite the severe defect in mobilization of HSPC in OL 8 
mice, the protein level of CXCL12 in the BM extracellular fluid (BMEF) was 9 
decreased after G-CSF administration to the same extent as in WT mice (Figure 5A). 10 
The expression of Cxcl12 mRNA in the BM and bone was also down-regulated 11 
following G-CSF to the same level as in WT mice (Figures 5B and 5C). Furthermore, 12 
a CXCR4 antagonist, AMD3100, induced rapid mobilization of mature leukocytes 13 
and progenitors in OL mice as in WT mice (Figures 5D and 5E), which indicated that 14 
CXCL12/CXCR4 axis was functional in the absence of osteocytes. These data 15 
suggested that the reduction of CXCL12 in the BM would not be sufficient for the 16 
regulation of G-CSF-induced mobilization by osteocytes.  17 
Intriguingly, the expression level of cxcl12 was increased both in the BM 18 
 13 
and bone by osteocyte ablation itself (Figures 5B and 5C). The magnitude of 1 
increase was greater in the BM than in the bone sample. To test whether this 2 
increase of cxcl12 represented the alteration of niche function, we analyzed the cell 3 
cycle status of stem cells in OL mice. We found that osteocyte depletion induced 4 
quiescence of CD34-lineage-Sca-1+c-kit+ (CD34-LSK) cells (Figures 5F and 5G). 5 
These results suggested that osteocyte ablation altered the microenvironment in the 6 
BM and augmented the HSC function.   7 
As osteocytes extend dendritic processes into the marrow space near the 8 
endosteal surface (Kamioka et al., 2001), it is possible that osteocytes communicate 9 
with several cell types in the marrow. We tested whether the microenvironmental 10 
change after the ablation of osteocytes could be associated with SNS. However, it 11 
was unlikely because TH staining showed no alteration in OL mice BM (data not 12 
shown). Recently, it has been reported that specific-tissue resident macrophages 13 
located in the endosteum have a pivotal role in supporting the endosteal niche. 14 
These macrophages, so called osteomacs (OM), are intercalated throughout bone 15 
forming osteoblasts, stretch their cell bodies over osteoblasts forming a canopy, and 16 
support osteoblasts function (Chang et al., 2008). The depletion of osteomacs in vivo 17 
leads to the disappearance of osteoblasts and the mobilization of HSPCs, which 18 
 14 
suggests their indispensable role for endosteal niche (Winkler et al., 2010). To 1 
assess the involvement of these osteomacs in osteocyte-mediated niche regulation, 2 
the F4/80-positive macrophages in the endosteum of OL mice were analyzed. We 3 
confirmed that F4/80-positive macrophages in BM expressed neither DMP-1 nor 4 
DTR transgene by RT-PCR (Figure 5H). Following DT treatment, osteomacs 5 
disappeared from the endosteum in Tg mice (Figures 5I-5K). Despite the loss of 6 
osteomacs, HSPC mobilization was not observed in the peripheral blood or in the 7 
spleen (Figures 4C and 4J), which suggested that suppression of osteomacs 8 
mediated by the osteocyte depletion was not sufficient for HSPC mobilization. These 9 
findings raised the possibility that osteocytes could be associated with osteomacs as 10 
one of the multiple regulatory pathways to control osteoblastic function.  11 
 12 
Disruption of Osteocyte Network and Impaired Mobilization in Klotho (kl/kl) 13 
mice 14 
Since osteocyte projections were affected by G-CSF treatment (Figures 2A 15 
and 2C) and osteocyte-deleted mice had severe mobilization defect (Figures 4B-4F), 16 
we hypothesized that the osteocyte network could be indispensable for HSPC 17 
mobilization. To test this hypothesis, we searched for another model with disrupted 18 
 15 
osteocyte network. Since klotho hypomorphic (kl/kl) mice had been reported to show 1 
osteoporosis with altered distribution of osteocytes (Kuro-o et al., 1997; Suzuki et al., 2 
2005), we thoroughly evaluated the osteocyte network, including the processes. 3 
Interestingly, we found that the osteocyte network of kl/kl mice in steady state was 4 
completely disrupted (Figure 6A) and resembled that of OL mice (Figure 4A). 5 
Strikingly, G-CSF-induced HSPC mobilization was severely impaired in kl/kl mice; 6 
whereas, the number of progenitors in the BM was comparable to that of WT mice 7 
(Figures 6B-6G). These data further suggested that the integrity of the osteocyte 8 




New Player in Endosteal Niche Regulation 2 
In the current study, it is demonstrated that the most mature osteo-lineage 3 
cell, osteocyte, is an important regulator of endosteal HSPC niche. Figure 6H 4 
summarizes the possible communication of multiple players. In light of the findings 5 
that ablation of osteocytes leads to dysfunction of osteoblasts (Figures 4L-4R) and 6 
disappearance of osteomacs (Figures 5H-5K), it is plausible that osteocytes may 7 
send supporting signals directly to the endosteal niche and indirectly via a 8 
maintenance signal to the macrophages (Figure 6H, left panel). These supporting 9 
signals for endosteal niche may take the balance with a negative signal from the SNS 10 
in steady state to maintain homeostasis.  11 
In the process of mobilization, G-CSF inclines this balance by 1) direct 12 
suppression of osteoblasts by increased sympathetic tone (Katayama et al., 2006; 13 
Kawamori et al., 2010) and 2) suppression of macrophages (Christopher et al., 2011; 14 
Winkler et al., 2010). Now, this study discovered the third major pathway: 15 
suppression of osteocytes in the bone through an increased sympathetic tone. Thus, 16 
according to our view, G-CSF mobilizes HSPCs by inducing triple negative effects on 17 
the endosteal niche, thereby leading to its collapse (Figure 6H, right panel). Our 18 
 17 
findings further support the concept of “brain-bone-blood triad” (Spiegel et al., 2008) 1 
with the bone as a pivotal hinge for the regulation of niche function. 2 
 3 
Regulation of Hematopoiesis by Osteocytes  4 
The best known function of osteocytes is mechanosensation. Recently, an 5 
osteocyte ablation model has provided in vivo evidence that osteocytes sense 6 
loading to the skeleton and orchestrate bone remodeling by controlling both 7 
osteoblasts and osteoclasts (Tatsumi et al., 2007). Unloading condition to the bone, 8 
as seen in long-term bedridden patients or astronauts during space flight, causes a 9 
rapid loss of bone mass, which indicates that the mechanical strain is indispensable 10 
for skeletal integrity. Furthermore, it has been reported that microgravity leads to the 11 
dysfunction of the immune system (Crucian and Sams, 2009). These changes in 12 
hematopoietic cells under microgravity are thought to be intrinsic to cells. However, 13 
extrinsic signals from the hematopoietic microenvironment should be considered 14 
now that we have demonstrated that mechanosensory osteocytes regulate the 15 
function of the HSPC niche. 16 
The exact mechanism how osteocytes regulate the HSPC niche is still 17 
unclear. Osteocytes produce anabolic signals that keep osteoblasts active, such as 18 
 18 
prostaglandin E2, nitric oxide, and adenosine triphosphate, in response to 1 
mechanical stress in vitro (Genetos et al., 2007; Klein-Nulend et al., 1995). They also 2 
regulate osteoblast behavior by the secretion of Wnt inhibitors, such as sclerostin 3 
and Dickkopf1 (Bonewald and Johnson, 2008). Recently, Sugimura et al. reported 4 
the switch of Wnt pathway in the osteoblastic niche from noncanonical to canonical 5 
signaling under stress (Sugimura et al., 2012). Wnt pathway between the HSC and 6 
osteoblastic niches might be influenced by osteocytes through secreted factors or 7 
direct contact with their projections. A few studies attempted to show the role of 8 
osteocytes for hematopoiesis. Calvi et al. reported that the activation of parathyroid 9 
hormone receptor signaling led to the expansion of osteoblasts and HSCs (Adams et 10 
al., 2007; Calvi et al., 2003). Then they tried to recapitulate this effect by the 11 
activation of this signaling only in osteocytes, but no HSC expansion was observed 12 
(Calvi et al., 2012). Fulzele et al. showed that osteocytes produced hematopoietic 13 
cytokines, such as G-CSF, at a certain level in steady state, and the deletion of Gs 14 
specifically in osteocytes greatly enhanced this production, which led to the 15 
expansion of myeloid-committed cells but not HSPCs in the BM (Fulzele et al., 2013). 16 
Although the exact signaling pathways from osteocytes to osteoblastic niches remain 17 
to be elucidated, our present study demonstrates for the first time that G-CSF may 18 
 19 
suppress these signals in association with the reduction of osteocyte projections to 1 
osteoblasts. Osteocytes regulate osteoblastic activity through gap junctional 2 
intercellular communication during stimulation by mechanical load. A recent study 3 
showed that conditional deletion of connexin-43 (Cx43), the main gap junctional 4 
protein in the osteolineage cells, led to dysfunction of osteoblasts and mobilization 5 
defect by G-CSF (Gonzalez-Nieto et al., 2012). Considering our findings, it is 6 
possible that this might be due to the disruption of functional communication between 7 
osteocytes and osteoblasts. 8 
 9 
Alteration of Bone Metabolism and Impaired G-CSF-Induced HSPC 10 
Mobilization 11 
The reduction of CXCL12, a potent retention factor of HSPC in the BM, has 12 
been proposed to be a main pathway that regulates HSPC egress from BM by 13 
G-CSF (Levesque et al., 2003; Petit et al., 2002). In the present study, however, 14 
osteocyte-ablated mice showed severe mobilization defect despite prompt reduction 15 
of CXCL12 in the BM. In addition, we have previously demonstrated that both 16 
UDP-galactose ceramide galactosyltransferase-deficient (Cgt-/-) (Katayama et al., 17 
2006) and vitamin D receptor-deficient (Vdr-/-) mice (Kawamori et al., 2010) showed 18 
 20 
severe defect in G-CSF-induced mobilization despite the prompt CXCL12 reduction 1 
in the BM. A common feature among these three models of mobilization defect was 2 
the alteration or dysfunction of osteoblasts with normal numbers of HSPCs in the BM. 3 
First, in Cgt-/- mice, osteoblasts were altered morphologically and functionally; 4 
wherein, they were flattened and serum osteocalcin level was low in steady state 5 
probably due to the neuronal abnormality. Second, Vdr-/- showed lack of osteoblastic 6 
niche suppression by G-CSF-induced catecholaminergic signal. Third, osteocyte 7 
depletion led to morphologic and functional alteration in the osteoblasts in the current 8 
study. In addition, a recent study showed that selective deletion of osteoblasts 9 
caused impairment of G-CSF-induced HSPC mobilization (Ferraro et al., 2011). 10 
According to these data, we speculate that a rapid collapse of intact osteoblasts, 11 
perhaps together with macrophages, would be needed for G-CSF-induced HSPC 12 
mobilization. Furthermore, subacute or chronic osteoblast alteration may lead to the 13 
induction of strong anchor proteins other than CXCL12 or the compensatory support 14 
by other niche cells. Further studies are necessary to clarify the exact mechanism.  15 
 16 
Possible Association of Osteocytes with Various Types of Niche Cells in BM 17 
In addition to endosteal osteoblasts, recent vigorous investigations have 18 
 21 
revealed the existence of perivascular niche (Ding et al., 2012; Mendez-Ferrer et al., 1 
2010; Omatsu et al., 2010; Yamazaki et al., 2011). Since the perivascular niche cells 2 
of mesenchymal origin, such as CXCL12-abundant reticular cells (Omatsu et al., 3 
2010) and nestin-positive mesenchymal stem cells (Mendez-Ferrer et al., 2010), can 4 
give rise to osteoblasts, there might be intermediate cells that differentiate from 5 
perivascular niche to osteoblasts and connect with each other throughout the BM. 6 
Our study expanded this mesenchymal syncytium as a regulatory network for niche 7 
function to the bone tissue. Given the fact that osteocyte depletion led to the increase 8 
of cxcl12 expression in the BM, which could be possibly associated with increased 9 
quiescence in HSCs (Figures 5B and 5G), osteocytes could have a modulating effect 10 
not only on the osteoblasts but also on the perivascular niche cells.  11 
More than a decade ago, Marotti proposed a novel signal transmission 12 
model linking three types of cells of osteogenic lineage (stromal cells, osteoblasts or 13 
bone-lining cells, and osteocytes); wherein, all cells were connected not only through 14 
volume transmission (paracrine and autocrine stimulations) but also by wiring 15 
transmission (cytoplasmic direct contact) (Marotti, 2000). According to this concept, 16 
three osteogenic lineage cells communicate from inside the bone to the vasculature 17 
in central BM, which imply that certain signals imposed on the skeletal system are 18 
 22 
spread immediately from calcified bone to soft BM and vice versa. In view of our 1 
findings on the novel function of osteocytes as a niche regulator, as well as other 2 
studies on osteoblastic and perivascular niches, the wiring transmission system may 3 
constitute a continuous syncytium of niche cells throughout the skeleton that 4 
contains the BM as part of it. 5 
 6 
        7 




EXPERIMENTAL PROCEDURES 1 
Animals 2 
C57BL/6J and klotho (kl/kl) mice were purchased from Japan CLEA (Chiba, 3 
Japan), and C57BL/6-CD45.1 congenic mice were purchased from The Jackson 4 
Laboratory (Bar harbor, ME, USA). DMP-1 DTR Tg mice were generated as 5 
described previously (Tatsumi et al., 2007), and all experiments were carried out 6 
using littermates. Animals were maintained under specific pathogen-free condition 7 
and on 12h light/12h darkness cycles. Peripheral blood collection was carried out by 8 
retro-orbital sinus bleeding with heparinized micro-capillary tube under deep 9 
anesthesia. Diphtheria toxin (DT, Sigma-Aldrich Japan, Tokyo, Japan) was 10 
administered intraperitoneally at 50 µg/kg to 6.5−8.5-wk-old DMP-1 DTR Tg or 11 
littermate WT mice. In any mobilization protocol, samples were harvested and 12 
assayed at 11 days after DT injection. All experimental procedures were approved by 13 
the Animal Care and Use Committee of Kobe University and Okayama University. 14 
 15 
Mobilization of HSPCs 16 
Mobilization of HSPCs was induced as described previously (Kawamori et 17 
al., 2010). Briefly, mice were injected with recombinant human G-CSF (Filgrastim, 18 
 24 
Kyowa Kirin, Tokyo, Japan, 250µg/kg/day every 12h in eight divided doses unless 1 
otherwise indicated, s.c.) in phosphate buffered saline (PBS) supplemented with 2 
0.1% bovine serum albumin (BSA) and were bred 3h following the last dose of 3 
G-CSF. AMD3100 (Sigma-Aldrich Japan, 5mg/kg, s.c.) in PBS was administered and 4 
mice were bred at 1h following the injection.  5 
The number of colony-forming unit in culture (CFU-C) in the peripheral 6 
blood, bone marrow, and spleen was assessed as previously described (Kawamori 7 
et al., 2010). Stem cell activities of blood mobilized by G-CSF were assessed by 8 
long-term competitive reconstitution as described previously (Kawamori et al., 2010). 9 
Briefly, 150µl of mobilized blood was mixed with 2×105 bone marrow nucleated cells 10 
from CD45.1 competitor donor and were together injected via the tail vein into lethally 11 
irradiated (14Gy, two split doses) CD45.1 recipient mice. The proportion of peripheral 12 
blood leukocytes bearing CD45.1 or CD45.2 antigen was determined monthly after 13 
transplantation by flow cytometry. The repopulating units (RUs) were calculated 14 
using the following standard formula: RU=%(C) / (100-%), where % is the 15 
measured % of donor cells (CD45.2+ cells derived from mobilized blood) and C is the 16 
number of competitor marrow cells per 105 .  17 
 18 
 25 
Bone cell isolation from long bones 1 
Bone cell isolation was performed according to the report by Stern et al. 2 
(Stern et al., 2012). Briefly, long bones (bilateral femora, tibias, and humeri) were 3 
isolated from 1 dose of vehicle- or G-CSF- (125g/kg/dose, s.c.) treated C57BL/6J 4 
(8-9 week-old male) mice 3 hours after the treatment. The bones from 4-5 mice per 5 
group were pooled together and treated as one sample. The epiphysis of the femurs, 6 
tibias, and humeri were removed, the bone marrow was flushed out with -minimal 7 
essential medium (-MEM), and the periosteum was mechanically removed using 8 
scalpel. The bones that were cut into small pieces were enzymatically digested three 9 
times (25 minutes each) with 2.5 mg/ml typeA collagenase (Sigma-Aldrich Japan) 10 
dissolved in -MEM. These fractions (Fra) were collected as Fra 1 to Fra 3. 11 
Thereafter, the bone pieces were digested with collagenase solution or 5 mM 12 
ethylenediaminetetraacetic acid tetrasodium salt dehydrate (Sigma-Aldrich Japan) 13 
solution alternately into 10 fractions. Following each digestion, the digest solution 14 
was removed and set aside, bone pieces were rinsed with Hank’s balanced salt 15 
solution (HBSS) three times, and each rinsate was mixed with the digest solution. 16 
The cells in Fra 1 and 2, Fra 3 and 4, Fra 5 and 6, Fra 7 and 8, and Fra 9 and 10 17 
were combined into one sample and then analyzed.      18 
 26 
 1 
Statistical Analysis 2 
All values were reported as mean ± SEM. Statistical significance was 3 
assessed by Student’s t test for two unpaired groups. Statistical significance was 4 
expressed as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not 5 
significant. 6 
 7 
SUPPLEMENTAL INFORMATION 8 
Supplemental information includes Supplemental Experimental Procedures (flow 9 
cytometry, tissue preparation, immunofluorescence and immunohistochemistry, 10 
quantification of osteoblast height, osteocalcin-positive osteoblast quantification, 11 
OsteoMac quantification, F4/80-positive macrophage sorting, homing assay, protein 12 
extraction from bone marrow, ELISA, RNA isolation, reverse transcription and 13 
quantitative real-time PCR, surgical denervation), two figures, and one table together 14 
with this article online.  15 
 16 
ACKNOWLEDGMENTS 17 
We would like to thank the following: Drs. Hidetsugu Tsujigiwa and Hitoshi 18 
 27 
Nagatsuka (Okayama University) for the technical help and valuable suggestions on 1 
immunohistological analysis of bone; Dr. Hiroshi Kamioka (Okayama University) for 2 
the superb advice about osteocyte staining and for stimulating discussions; Dr. 3 
Toshitaka Oohashi (Okayama University) for the technical help on making frozen 4 
sections. This work was supported by the Grants-in-Aid for Scientific Research from 5 
Japan Society for the Promotion of Science (#23390251 to Y. Katayama) and for 6 
Scientific Research on Innovative Areas from the Ministry of Education, Culture, 7 
Sports, Science and Technology in Japan (#23118517 to Y. Katayama). 8 
N.A. performed all experiments and wrote the manuscript; M.S., K.M., K.W., 9 
H.K., Y. Kawano and A.S. helped with animal maintenance, tissue sample 10 
preparation, and qRT-PCR. K.I. and T.M. supervised the studies for DMP-1 DTR Tg 11 
mice. M.T. supervised the studies for surgical denervation and kl/kl mice. Y. 12 
Katayama supervised all experiments and wrote the manuscript. 13 
Conflict of interest disclosure: The authors declare no competing financial 14 





Adams, G.B., Martin, R.P., Alley, I.R., Chabner, K.T., Cohen, K.S., Calvi, L.M., 3 
Kronenberg, H.M., and Scadden, D.T. (2007). Therapeutic targeting of a stem cell 4 
niche. Nature biotechnology 25, 238-243. 5 
 6 
Arai, F., Hirao, A., Ohmura, M., Sato, H., Matsuoka, S., Takubo, K., Ito, K., Koh, G.Y., 7 
and Suda, T. (2004). Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell 8 
quiescence in the bone marrow niche. Cell 118, 149-161. 9 
 10 
Bonewald, L.F. (2011). The amazing osteocyte. J Bone Miner Res 26, 229-238. 11 
 12 
Bonewald, L.F., and Johnson, M.L. (2008). Osteocytes, mechanosensing and Wnt 13 
signaling. Bone 42, 606-615. 14 
 15 
Calvi, L.M., Adams, G.B., Weibrecht, K.W., Weber, J.M., Olson, D.P., Knight, M.C., 16 
Martin, R.P., Schipani, E., Divieti, P., Bringhurst, F.R., et al. (2003). Osteoblastic 17 
cells regulate the haematopoietic stem cell niche. Nature 425, 841-846. 18 
 19 
Calvi, L.M., Bromberg, O., Rhee, Y., Weber, J.M., Smith, J.N., Basil, M.J., Frisch, 20 
B.J., and Bellido, T. (2012). Osteoblastic expansion induced by parathyroid hormone 21 
receptor signaling in murine osteocytes is not sufficient to increase hematopoietic 22 
stem cells. Blood 119, 2489-2499. 23 
 24 
Chang, M.K., Raggatt, L.J., Alexander, K.A., Kuliwaba, J.S., Fazzalari, N.L., 25 
Schroder, K., Maylin, E.R., Ripoll, V.M., Hume, D.A., and Pettit, A.R. (2008). Osteal 26 
tissue macrophages are intercalated throughout human and mouse bone lining 27 
tissues and regulate osteoblast function in vitro and in vivo. J Immunol 181, 28 
1232-1244. 29 
 30 
Chow, A., Lucas, D., Hidalgo, A., Mendez-Ferrer, S., Hashimoto, D., Scheiermann, 31 
C., Battista, M., Leboeuf, M., Prophete, C., van Rooijen, N., et al. (2011). Bone 32 
marrow CD169+ macrophages promote the retention of hematopoietic stem and 33 
progenitor cells in the mesenchymal stem cell niche. J Exp Med 208, 261-271. 34 
 35 
Christopher, M.J., and Link, D.C. (2008). Granulocyte colony-stimulating factor 36 
induces osteoblast apoptosis and inhibits osteoblast differentiation. J Bone Miner 37 
 29 
Res 23, 1765-1774. 1 
 2 
Christopher, M.J., Rao, M., Liu, F., Woloszynek, J.R., and Link, D.C. (2011). 3 
Expression of the G-CSF receptor in monocytic cells is sufficient to mediate 4 
hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 208, 251-260. 5 
 6 
Crucian, B., and Sams, C. (2009). Immune system dysregulation during spaceflight: 7 
clinical risk for exploration-class missions. J Leukoc Biol 86, 1017-1018. 8 
 9 
Ding, L., Saunders, T.L., Enikolopov, G., and Morrison, S.J. (2012). Endothelial and 10 
perivascular cells maintain haematopoietic stem cells. Nature 481, 457-462. 11 
 12 
Ferraro, F., Lymperi, S., Mendez-Ferrer, S., Saez, B., Spencer, J.A., Yeap, B.Y., 13 
Masselli, E., Graiani, G., Prezioso, L., Rizzini, E.L., et al. (2011). Diabetes impairs 14 
hematopoietic stem cell mobilization by altering niche function. Science translational 15 
medicine 3, 104ra101. 16 
 17 
Fulzele, K., Krause, D.S., Panaroni, C., Saini, V., Barry, K.J., Liu, X., Lotinun, S., 18 
Baron, R., Bonewald, L., Feng, J.Q., et al. (2013). Myelopoiesis is regulated by 19 
osteocytes through Gsalpha-dependent signaling. Blood 121, 930-939. 20 
 21 
Genetos, D.C., Kephart, C.J., Zhang, Y., Yellowley, C.E., and Donahue, H.J. (2007). 22 
Oscillating fluid flow activation of gap junction hemichannels induces ATP release 23 
from MLO-Y4 osteocytes. Journal of cellular physiology 212, 207-214. 24 
 25 
Gonzalez-Nieto, D., Li, L., Kohler, A., Ghiaur, G., Ishikawa, E., Sengupta, A., Madhu, 26 
M., Arnett, J.L., Santho, R.A., Dunn, S.K., et al. (2012). Connexin-43 in the 27 
osteogenic BM niche regulates its cellular composition and the bidirectional traffic of 28 
hematopoietic stem cells and progenitors. Blood 119, 5144-5154. 29 
 30 
Kamioka, H., Honjo, T., and Takano-Yamamoto, T. (2001). A three-dimensional 31 
distribution of osteocyte processes revealed by the combination of confocal laser 32 
scanning microscopy and differential interference contrast microscopy. Bone 28, 33 
145-149. 34 
 35 
Katayama, Y., Battista, M., Kao, W.M., Hidalgo, A., Peired, A.J., Thomas, S.A., and 36 
Frenette, P.S. (2006). Signals from the sympathetic nervous system regulate 37 
 30 
hematopoietic stem cell egress from bone marrow. Cell 124, 407-421. 1 
 2 
Kawamori, Y., Katayama, Y., Asada, N., Minagawa, K., Sato, M., Okamura, A., 3 
Shimoyama, M., Nakagawa, K., Okano, T., Tanimoto, M., et al. (2010). Role for 4 
vitamin D receptor in the neuronal control of the hematopoietic stem cell niche. Blood 5 
116, 5528-5535. 6 
 7 
Klein-Nulend, J., van der Plas, A., Semeins, C.M., Ajubi, N.E., Frangos, J.A., 8 
Nijweide, P.J., and Burger, E.H. (1995). Sensitivity of osteocytes to biomechanical 9 
stress in vitro. FASEB journal : official publication of the Federation of American 10 
Societies for Experimental Biology 9, 441-445. 11 
 12 
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, 13 
Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997). Mutation of the mouse 14 
klotho gene leads to a syndrome resembling ageing. Nature 390, 45-51. 15 
 16 
Levesque, J.P., Hendy, J., Takamatsu, Y., Simmons, P.J., and Bendall, L.J. (2003). 17 
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem 18 
cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111, 187-196. 19 
 20 
Marotti, G. (2000). The osteocyte as a wiring transmission system. J Musculoskelet 21 
Neuronal Interact 1, 133-136. 22 
 23 
Mendez-Ferrer, S., Lucas, D., Battista, M., and Frenette, P.S. (2008). 24 
Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452, 25 
442-447. 26 
 27 
Mendez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R., Macarthur, B.D., Lira, 28 
S.A., Scadden, D.T., Ma'ayan, A., Enikolopov, G.N., and Frenette, P.S. (2010). 29 
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. 30 
Nature 466, 829-834. 31 
 32 
Omatsu, Y., Sugiyama, T., Kohara, H., Kondoh, G., Fujii, N., Kohno, K., and 33 
Nagasawa, T. (2010). The essential functions of adipo-osteogenic progenitors as the 34 
hematopoietic stem and progenitor cell niche. Immunity 33, 387-399. 35 
 36 
Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, 37 
 31 
T., Taichman, R.S., Arenzana-Seisdedos, F., Fujii, N., et al. (2002). G-CSF induces 1 
stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. 2 
Nat Immunol 3, 687-694. 3 
 4 
Spiegel, A., Kalinkovich, A., Shivtiel, S., Kollet, O., and Lapidot, T. (2008). Stem cell 5 
regulation via dynamic interactions of the nervous and immune systems with the 6 
microenvironment. Cell stem cell 3, 484-492. 7 
 8 
Stern, A.R., Stern, M.M., Van Dyke, M.E., Jahn, K., Prideaux, M., and Bonewald, L.F. 9 
(2012). Isolation and culture of primary osteocytes from the long bones of skeletally 10 
mature and aged mice. BioTechniques 52, 361-373. 11 
 12 
Sugimura, R., He, X.C., Venkatraman, A., Arai, F., Box, A., Semerad, C., Haug, J.S., 13 
Peng, L., Zhong, X.B., Suda, T., et al. (2012). Noncanonical Wnt signaling maintains 14 
hematopoietic stem cells in the niche. Cell 150, 351-365. 15 
 16 
Suzuki, H., Amizuka, N., Oda, K., Li, M., Yoshie, H., Ohshima, H., Noda, M., and 17 
Maeda, T. (2005). Histological evidence of the altered distribution of osteocytes and 18 
bone matrix synthesis in klotho-deficient mice. Archives of histology and cytology 68, 19 
371-381. 20 
 21 
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, 22 
S., and Ikeda, K. (2007). Targeted ablation of osteocytes induces osteoporosis with 23 
defective mechanotransduction. Cell Metab 5, 464-475. 24 
 25 
Taylor, A.F., Saunders, M.M., Shingle, D.L., Cimbala, J.M., Zhou, Z., and Donahue, 26 
H.J. (2007). Mechanically stimulated osteocytes regulate osteoblastic activity via gap 27 
junctions. Am J Physiol Cell Physiol 292, C545-552. 28 
 29 
Visnjic, D., Kalajzic, Z., Rowe, D.W., Katavic, V., Lorenzo, J., and Aguila, H.L. (2004). 30 
Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. 31 
Blood 103, 3258-3264. 32 
 33 
Wang, L.D., and Wagers, A.J. (2011). Dynamic niches in the origination and 34 




Winkler, I.G., Sims, N.A., Pettit, A.R., Barbier, V., Nowlan, B., Helwani, F., Poulton, 1 
I.J., van Rooijen, N., Alexander, K.A., Raggatt, L.J., et al. (2010). Bone marrow 2 
macrophages maintain hematopoietic stem cell (HSC) niches and their depletion 3 
mobilizes HSCs. Blood 116, 4815-4828. 4 
 5 
Yamazaki, S., Ema, H., Karlsson, G., Yamaguchi, T., Miyoshi, H., Shioda, S., Taketo, 6 
M.M., Karlsson, S., Iwama, A., and Nakauchi, H. (2011). Nonmyelinating Schwann 7 
cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 8 
147, 1146-1158. 9 
 10 
Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W.G., Ross, J., Haug, J., Johnson, 11 
T., Feng, J.Q., et al. (2003). Identification of the haematopoietic stem cell niche and 12 





FIGURE LEGENDS 1 
Figure 1. Changes in Gene Expression during G-CSF-Induced Mobilization 2 
(A) Protocol for HSPC mobilization by G-CSF (filgrastim 125g/kg/dose, s.c.). (B) 3 
Number of CFU-Cs in the peripheral blood at each timing of G-CSF administration 4 
(n=3). (C) Quantitative (q) RT-PCR analysis of osteoblast markers (Osteocalcin, type 5 
1 collagen (Col1a1), and Osteopontin) and osteocyte markers (E11/gp38, Matrix 6 
extracellular phosphoglycoprotein (MEPE), Phosphate regulating endopeptidase 7 
homolog X-linked (Phex), sclerostin (SOST), neuropeptide y (NPY), and dentin 8 
matrix protein-1 (DMP-1)) in the femur after the indicated dose of G-CSF 9 
administration. Data were normalized to  -actin and pooled from 2 or 3 10 
independent experiments. n=6-9 mice per group. (D) RT-PCR analysis of 11 
osteoblastic and osteocytic markers in enzymatically isolated cells from long bones 12 
after one dose of G-CSF treatment. Data were normalized to -actin and pooled 13 
from 8 independent experiments. n=8 per group. Data are represented as mean +/- 14 
standard error of the mean (SEM). Fr: Fraction. See also Table S1. 15 
 16 
Figure 2. Morphological Change in Osteocyte by G-CSF Treatment 17 
(A) Alexa488-conjugated phalloidin staining of bone tissues treated with vehicle (left 18 
panel) or G-CSF (right panel). Representative pictures from three different sets of 19 
 34 
experiment are shown. The scale bars show 20m. (B) Alexa488-conjugated 1 
phalloidin staining of femur to show the location of analysis in C and D. (C,D) 2 
Alexa488-conjugated phalloidin staining of osteocytes near the endosteal region (C) 3 
and deeply embedded ones (D). Osteocyte Projection Index is described in the 4 
supplemental experimental procedures. The bar graphs show osteocyte projection 5 
index in different parts of the bone. The mean of three representative osteocytes in 6 
one field was calculated as one value. Three different areas from each part were 7 
analyzed. Data from three different mice were combined (n=9). Scale bar indicates 58 
m. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Data are represented as 9 
mean +/- SEM. P/B: PBS/BSA (vehicle). 10 
 11 
Figure 3. Involvement of Sympathetic Nervous System in the Effect of G-CSF 12 
on Osteocytes 13 
(A) Immunofluorescence staining of tyrosine hydroxylase-positive sympathetic 14 
neurons in the endosteum.  Green: tyrosine hydroxylase, Red: phalloidin. Black 15 
area indicates the bone. The scale bars indicate 20m. (B) Immunofluorescence 16 
staining of 2-AR in the endosteal region. Frozen section. Green: 2-AR, Blue: 17 
DAPI.  The scale bars indicate 20m. (C) Immunohistochemistry of 2-AR of 18 
 35 
paraffin-embedded bone sections. Scale bar indicates 50m (20m in enlarged 1 
picture). (D) Immunohistochemistry of 2-AR in paraffin-embedded bone sections 2 
focusing on the projections of osteocytes. Scale bar indicates 10m. (E) qRT-PCR 3 
analysis of the tibia following 2 doses of G-CSF after surgical denervation or 4 
contralateral sham operation (SHM; sham-operated bone, DEN; denervated bone). 5 
Data were normalized to -actin and pooled from 3 independent experiments. 6 
n=6-9. * P < 0.05; ** P < 0.01. Data are represented as mean +/- SEM. See also 7 
Figure S1 and Table S1. 8 
 9 
Figure 4. Severely Impaired G-CSF-induced mobilization by Osteocyte 10 
Ablation 11 
(A) Alexa488-conjugated phalloidin staining of bone tissues at 11 days after DT 12 
administration. The scale bars show 20m. (B) Peripheral blood white blood cell 13 
(WBC) count (n=5-8), (C) CFU-Cs in 1ml of peripheral blood (n=4-7), (D) 14 
Lineage-Sca-1+c-kit+ (LSK) cells in 1ml peripheral blood (n=5-8) after 8 doses of 15 
G-CSF. (E) The %CD45.2 donor-derived cell in competitive reconstitution of 16 
mobilized blood (n=6-7). Mobilized peripheral blood (150L, CD45.2) was mixed 17 
with CD45.1 competitor bone marrow cells and injected into irradiated CD45.1 18 
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recipient mice. (F) Calculated RU at 4 months (n=6-7). (G) Bone marrow cellularity 1 
per femur (n=6-7). (H) CFU-Cs per femur (n=5-8). (I) Percent of CD45.2 2 
donor-derived cell in competitive reconstitution of bone marrow cells (n=6-8). (J) 3 
CFU-Cs in the spleen at 10 days after DT treatment (n=4-5). (K) Homing ability of 4 
CFU-C in DMP-1 DTR WT or Tg mice (n=5 per group). (L) Hematoxylin and Eosin 5 
staining of the femoral endosteum at 11 days after DT administration. Arrows 6 
indicate osteoblasts. Arrowheads indicate empty lacunae. Scale bars indicate 207 
m. (M) Quantification of osteoblast (OB) height (n=27). (N) Osteocalcin mRNA 8 
expression in femoral bone (qRT-PCR, n=6). (O) Osteocalcin protein level in plasma 9 
(n=6-7). (P) Immunofluorescence staining of osteocalcin in femoral bone at 10 days 10 
after DT treatment in WT and DMP-1 DTR Tg mice. Scale bars indicate 100m. 11 
(Q,R) Histomorphometric indices. Quantification of osteocalcin-positive osteoblasts 12 
at 10 days after DT treatment in WT and DMP-1 DTR Tg mice. Osteocalcin-positive 13 
osteoblast surface per bone surface (ObS/BS; Q). Osteocalcin-positive cell number 14 
per mm bone surface (ObN/BS; R). Analysis was done on three different areas of the 15 
metaphysis per mouse. Three mice per group were analyzed. * P < 0.05; ** P < 0.01; 16 
*** P < 0.001; **** P < 0.0001. Data are represented as mean +/- SEM. See also 17 
Figure S2 and Table S1. 18 
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 1 
Figure 5. Altered Niche Regulating Cells in the BM by Osteocyte Ablation 2 
(A) CXCL12 protein in BM extracellular fluid (BMEF) after 8 doses of G-CSF (n=6-7). 3 
(B,C) The expression levels of Cxcl12 mRNA of bone marrow cells (B), bone (C) 4 
from WT and DMP-1 DTR Tg mice (n=6). (D) White blood cell (WBC) count in 5 
peripheral blood at 1 hour after AMD3100 injection (PBS, n=3-4; AMD3100, n=8-10). 6 
(E) AMD3100-induced mobilization. CFU-Cs in 1 ml peripheral blood (PBS; n=3-4; 7 
AMD3100; n=8-10). (F,G) Cell cycle analysis of bone marrow CD34(-) LSK cells in 8 
DMP-1 DTR WT and Tg mice at 10 days after DT treatment (n=5-6). (H) RT-PCR of 9 
DMP-1 and DTR. Lanes 1 and 2 indicate bone sample and F4/80-positive cells 10 
isolated from DMP-1 DTR Tg mice, respectively. Representative data from two 11 
different sets of experiment are shown. (I) Immunohistochemistry of F4/80 antigen in 12 
femoral bone after DT treatment in WT and DMP-1 DTR Tg mice. Scale bars indicate 13 
50µm in original images and 20µm in insets. Images are representative of 3 mice. 14 
(J,K) Histomorphometric indices. Quantification of F4/80-positive osteomacs (OM) in 15 
femoral bone at 11 days after DT treatment in WT and DMP-1 DTR Tg mice. 16 
Osteomacs covering surface per bone surface (OM surface/BS; J). OM number per 17 
mm bone surface (OM number/BS; K). Analysis was done on three different areas of 18 
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the metaphysis per mouse. Three mice per group were analyzed. Data are 1 
represented as mean +/- SEM. See also Table S1. 2 
Figure 6. Severely Impaired G-CSF-Induced Mobilization in Klotho (kl/kl) Mice - 3 
Another Model with Disrupted Osteocyte Network 4 
(A) Disrupted osteocyte network in klotho hypomorphic (kl/kl) mice in the cortical 5 
(upper panels) and trabecular (lower panels) bones in steady-state. The scale bars 6 
indicate 20m. Representative pictures from two mice of each genotype are shown. 7 
(B-D) Mobilization by G-CSF (8 doses) was severely impaired in kl/kl mice.  The 8 
number of WBC (B), CFU-Cs (C), and LSK cells (D) mobilized to peripheral blood by 9 
G-CSF in kl/kl mice and WT littermates (n=5). Data were pooled from two 10 
independent experiments. Cellularity (E), CFU-Cs (F), and LSK cells (G) in the bone 11 
marrow of one femur after the administration of G-CSF (n=5). Data were pooled from 12 
2 independent experiments. * P < 0.05; ** P < 0.01. Data are represented as mean 13 
+/- SEM. (H) Model for the role of osteocytes in niche regulation. In steady state (left 14 
panel), osteocytes and osteomacs (M) send signals to maintain the function of the 15 
osteoblastic niche (red solid arrows). Osteocytes may also send a supporting signal 16 
to the osteomacs (dotted line). In G-CSF-induced mobilization (right panel), 17 
SNS-mediated 2-AR signaling suppresses not only osteoblastic but also osteocytic 18 
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Supplemental Figure Legends 
 
Supplemental Figure 1 related to Figure 3 
(A) Negative control for 2-AR staining of osteocytes (Figure 3D). Non-immunized 
rabbit IgG was used for primary antibody. Scale bar indicates 10m. (B) 
Immunofluorescence staining of tyrosine hydroxylase-positive autonomic nerve in 
sham-operated and denervated tibia. Scale bars show 100m. (C) qRT-PCR 
analysis at the tibia following 2 doses of G-CSF after surgical denervation or 
contralateral sham operation (SHM; sham-operated bone, DEN; denervated bone). 
Data were normalized to -actin and pooled from 3 independent experiments. 
n=6-9. * P < 0.05; ** P < 0.01. Error bars show the mean and the SEM. 
 
  
Supplemental Figure 2 related to Figure 4 
(A) HE staining of femoral bone from DT treated WT and DMP-1 DTR Tg mice. 
Bones were harvested at 2-3 days after DT injection. Arrows and arrowheads show 
osteoblasts and empty lacunae, respectively. Scale bars show 20m. Images are 
representative of 3 mice of each genotype. (B) Quantification of osteoblast (OB) 
height in metaphysis at 2-3 days after DT treatment (n=27). (C,D) Histomorphometric 
indices. Quantification of osteocalcin positive osteoblasts at 2-3 days after DT 
treatment in WT and DMP-1 DTR Tg mice. Osteocalcin positive osteoblast surface 
per bone surface (ObS/BS; C). Osteocalcin positive cell number per mm bone 
surface (ObN/BS; D). Analysis was done on three different areas of the metaphysis 







Supplemental Table 1 related to Figures 1, 3, 4 and 5  
Primers used for PCR. The PCR protocol consisted of one cycle at 95 (10min) 































Supplemental Experimental Procedures 
 
Flow cytometry 
All antibodies and procedures for flow cytometry except for cell cycle analysis of 
CD34(-) LSK cells were as described (Kawamori et. al., 2010). For cell cycle analysis 
of CD34(-) LSK cells, mononuclear cells (MNC) were separated using Ficoll-Conray 
solution (IBL, Fujioka, Japan) from the bone marrow isolated from the femurs and 
tibiae. CD117 (c-kit) positive cells were enriched with anti-mouse CD117 microbeads 
(Miltenyi Biotech, Gladbach, Germany) and autoMACS separator (Miltenyi Biotech) 
prior to staining. Cells were stained with LSK markers; biotinylated anti-mouse 
antibodies to CD11b, Gr-1, Ter119, CD3e, and B220 (BD Biosciences, San Jose, 
USA) followed by APC-Cy7-conjugated streptavidin (BD Biosciences), 
APC-conjugated c-kit (2B8, BioLegend, San Diego, USA), PE-Cy7-conjugated Sca-1 
(E13-161.7, BioLegend) and PE-conjugated CD34 (RAM34, eBioscience, San Diego, 
USA), and then fixed and permeabilized (Cytofix/Cytoperm kit, BD Biosciences), and 
incubated with Ki 67 FITC (BD Biosciences) for 20 min at room temperature. After 
washing, cells were resuspended in staining buffer containing 1  g/ml 
4’,6-diamino-2-phenylindole (DAPI).  
      All analyses were performed using FACSCallibur, FACSCan (BD 
Biosciences), and MACSQuant (Miltenyi Biotec) at Kobe University and Central 
Research Laboratory of Okayama University. Data analysis was performed with 
FlowJo (TreeStar, Ashland, USA).  
 
Tissue preparation  
Mice were deeply anesthetized with isoflurane and were given intracardiac perfusion 
with cold PBS (pH7.4) followed by 4% paraformaldehyde (PFA) (pH7.4) in PBS at 
4. Femurs and tibiae were isolated, post-fixed in 4% PFA at 4 overnight, and 
decalcified in 10% EDTA at 4 for 2 weeks. Before being embedded in SCEM 
(Leica Microsystems, Wetzlar, Germany), the tissue was cryoprotected for 24h in 
30% sucrose in PBS at 4. Some tissues were embedded in paraffin using general 
procedure. 
 
Immunofluorescence and immunohistochemistry 
For osteocyte projection staining, decalcified bone was cut with Cryostat (Leica 
Microsystems) using Kawamoto’s tape transfer method (Kawamoto, 2003). 
Longitudinal sections of femoral bones were prepared. The sections were rinsed 
three times with PBS and blocked in 2% BSA/PBS for 30min. Alexa488-conjugated 
 7 
phalloidin (Life Technologies Japan, Tokyo, Japan) was added and then incubated at 
4 in dark for 48 hours. After removal of excess phalloidin, the sections were rinsed 
three times with PBS and then mounted with Vectashield Mounting Medium with 
DAPI (Vector Laboratories, Burlingame, CA). Images were captured with an LSM510 
confocal laser scanning (CLS) microscopy system (Carl Zeiss, Oberkochen, 
Germany) coupled to an AxioPlan2 imaging upright microscopy (Carl Zeiss) at 
Central Research Laboratory, Okayama University Medical School. Confocal images 
were taken with 0.42µm step size, frame size of 146.2m x 146.2m with 8-bit 
color depth and then were processed four times with Kalman averaging. Obtained 
CLS images were reconstructed by IMARIS software (Carl Zeiss). All images were 
processed with same settings (baseline subtraction and threshold), and 40 slices 
were stacked and reconstructed in Figures 2A and 4A. The color of Alexa 
488-conjugated phalloidin was expressed digitally in red. For quantification of 
osteocyte projection, 20, 15, 20, 30, 20 slices were stacked and reconstructed for 
endosteal osteocytes at metaphysis, endosteal osteocytes at diaphysis, osteocytes 
at trabecular bone, deeply embedded osteocytes at metaphysis, and deeply 
embedded osteocytes at diaphysis, respectively. For the analysis of endosteal 
osteocytes, the number of projection that reached the osteoblasts was counted 
manually and indicated as osteocyte projection index. For quantification of deeply 
embedded osteocyte, the number of projection at 5m distance from cell body was 
counted and expressed as osteocyte projection index. Since osteocytes have polarity, 
the projection-rich side was used for quantification.     
For the immunohistochemistry of 2-adrenergic receptor (AR) and F4/80, 
paraffin-embedded 2 µm-thick sections were stained with Hematoxylin and Eosin to 
evaluate morphology. After inhibition of endogenous peroxidase activity with 
methanol-containing 0.3% hydrogen peroxidase for 30 min, antigen retrieval was 
done with citrate buffer (pH 6.0). Sections were blocked with normal serum of host 
animal for secondary antibody for 15 min. We used rabbit polyclonal anti-2-AR 
antibody (1:100, ab61778, Abcam Ltd., Cambridge, UK) and rat anti-mouse F4/80 
(1:100, MCA497, AbD serotec, Oxford, UK). Samples were visualized with 
HRP-polymer detection kit (K5027, Dako, Glustrup, Denmark) for  2-AR and 
VECTASTAIN Elite ABC kit (PK-6104, Vector laboratories) for F4/80, followed by the 
3,3’-diaminobenzidine substrate. Images were captured with inverted microscope 
(BZ8100, KEYENCE Japan, Osaka). 
For the immunofluorescence staining of 2-AR, frozen sections were 
incubated with rabbit anti-2-AR antibody (1:500, ab61778, Abcam Ltd.), visualized 
by Alexa 488-conjugated goat anti-rabbit immunoglobulin G (IgG; Life Technologies 
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Japan), and mounted in Vectashield Mounting Medium with DAPI (Vector 
Laboratories).  Images were captured with a confocal laser scanning microscope 
(LSM510, Carl Zeiss).  
For the immunofluorescence staining of tyrosine hydroxylase (TH), 20 
µm-thick frozen sections of femurs were incubated with rabbit anti-TH antibody 
(1:500, #AB152, Millipore Billerica, MA) and Alexa 555-conjugated phalloidin 
(A34055, Life technologies Japan) simultaneously and visualized by Alexa 
488-conjugated anti-rabbit IgG (A-11008, Life technologies Japan). Images were 
taken with 0.35µm step size, processed four times with Kalman averaging with a 
confocal laser scanning microscope (LSM510, Carl Zeiss), and then were stacked 
using LSM Image Browser v4.2 (Carl Zeiss). 
 
Quantification of osteoblast height  
To quantify the change in osteoblast after osteocyte ablation, we measured the 
height of osteoblast in metaphyseal endosteal surface of HE stained femur. Three 
different parts of 1 mm long endosteal region were captured with inverted 
microscope (BZ8100, KEYENCE Japan). The height of three representative 
osteoblasts in each high power field (60) were measured using BZ-H2A and 
BZ-H1M software (KEYENCE Japan). The mean value of three osteoblasts from 9 
different high power fields was obtained from one mouse. Three femurs from 
different mice were analyzed for each group.   
 
Osteocalcin positive osteoblast quantification 
Five m-thick frozen sections of femurs were incubated with monoclonal antibody 
to mouse osteocalcin (R21C-01A, TAKARA BIO INC., Japan) and visualized by 
Alexa 488-conjugated anti-rat IgG (Life Technologies Japan). Images of three 
different parts of metaphysis (approximately 1 mm long for each part) were captured. 
Osteocalcin positive cells covering the endosteal surface were marked, and the 
number per 1mm BS and percent of osteocalcin positive cell surface per 1 mm BS 
were calculated. Three femurs from different mice per group were analyzed. Images 
were captured and analyzed with inverted microscope (BZ8100, KEYENCE Japan) 
and software (BZ-H2A and BZ-H1M, KEYENCE Japan).    
 
OsteoMac quantification 
To quantify the change in osteomac after osteocyte deletion, we measured the 
percent of F4/80 positive osteomac covering surface per bone surface (BS) and the 
number of osteomac per 1mm BS at metaphysis. Three different parts of metaphysis 
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(approximately 1 mm long for each part) were captured. Three femurs from different 
mice per group were analyzed. Images were captured and analyzed with inverted 
microscope (BZ8100, KEYENCE Japan) and software (BZ-H2A and BZ-H1M, 
KEYENCE Japan).   
 
F4/80-positive macrophage sorting 
Bilateral femur and tibia were isolated from DMP-1 DTR Tg mice. BM were flushed 
out into PBS and kept on ice. Flushed out bones were cut into small pieces and 
incubated in 2mg/ml collagenase typeA (Sigma-Aldrich Japan) dissolved in PBS 
for 40min at 37. Bone pieces were rinsed three times with PBS, rinsate was spun 
down, and resuspended in PBS.  Flushed BM and collagenase-digested cells were 
combined into one sample. Cells were stained with phycoerythrin (PE)- conjugated 
F4/80 (CI:A3-1, BioLegend) for 30 minutes at 4. Cells were washed with staining 
buffer once and labeled with anti-PE microbeads (Miltenyi Biotec) for 15 min at 4. 
F4/80 positive cells were separated using autoMACS separator (Miltenyi Biotec). 





Homing assay of CFU-C 
Assay for hematopoietic progenitor homing was performed as described previously 
(Kawamori et.al., 2010) with minor modifications. Briefly, 10 million donor bone 
marrow nucleated cells from 8-9-week-old CD45.1 mice were injected into lethally 
irradiated (13 Gy, two split dose) 8-9-week-old DMP-1 DTR WT and Tg littermates. 
At 3 hours after injection, BM were harvested and transferred to CFU-C assay. The 
number of homed CFU-Cs per femur was corrected to represent the whole BM as 
described. CD45.1 donor cells were also plated for CFU-C assay to assess the 
numbers of CFU-Cs injected. Then, the percentage of homed progenitors to BM was 
calculated. n=5 from 2 independent experiments.   
 
Protein extraction from bone marrow 
Bone marrow extra-cellular fluid (BMEF) was obtained by flushing one femur with 
0.5ml of ice-cold PBS, and the supernatant was harvested after gentle pipetting 





ELISA for CXCL12 and osteocalcin was done exactly as previously described 
(Kawamori et al., 2010). 
 
RNA isolation, reverse transcription, and quantitative real time PCR 
After flushing out the bone marrow, femurs and tibiae were immediately 
cryopreserved in liquid nitrogen and stored at −80 freezer until further analysis. 
Samples were pulverized using CryoPress (MICROTECH, Chiba, Japan), mixed with 
1.5ml Trizol (Life Technologies Japan) and stored at −80. RNA extraction and 
quantitative (q) reverse transcription polymerase chain reaction (PCR) were 
performed exactly as described previously (Kawamori et al., 2010). Primers used are 
available in supplemental table 1. 
 
Surgical denervation 
Surgical denervation was done as described elsewhere (Mendez-Ferrer et al., 2008). 
Briefly, the femoral and sciatic nerves of C57BL/6J mice (7-8 week-old) were 
exposed under anesthesia with isoflurane and unilaterally sectioned with scissors. 
Sham operation was performed on the contralateral side in which the nerves were 
exposed in the same manner but were not sectioned. Two days after the surgery, 
G-CSF (125µg/kg/dose, 2 doses, s.c.) was administered to the animals, and the 
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